Our results underscore the importance of evaluating the IDH mutation subgroup status of ICC tumors in future clinical practice and provide critical information on the diagnosis, prognosis, and treatment of ICC tumors. This evidence concerns the gene IDH2 and intrahepatic cholangiocarcinoma.